Literature DB >> 24622853

[Actinic keratoses. Pathogenesis, clinical aspect and modern therapeutic options].

T Strunk1, R-M Szeimies.   

Abstract

Actinic keratoses primarily affect fair-skinned individuals over 50 years of age. Due to demographic changes, the prevalence of actinic keratoses has increased over the last years. An established risk factor is chronic UV-exposure (outdoor workers) inducing mutations of the tumor suppressor gene TP53 and the oncogene H-ras. This leads to an intraepidermal proliferation of atypical keratinocytes. The term "field cancerization" characterizes the presentation of multiple actinic keratoses in UV-exposed areas. Actinic keratoses are also termed squamous cell carcinoma (SCC) in situ. The risk for actinic keratoses to turn into a SCC is 6-10 %. Treatment should be provided early in the disease course to avoid the possibility of invasive growth. In recent years, multiple therapeutic options have been established. Depending on the clinical extent, lesion- or field-directed therapies with excellent clinical response and cosmetic results are available.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24622853     DOI: 10.1007/s00105-014-2759-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  56 in total

1.  Pathology and pathobiology of the actinic (solar) keratosis.

Authors:  C J Cockerell
Journal:  Br J Dermatol       Date:  2003-11       Impact factor: 9.302

Review 2.  [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma].

Authors:  R-M Szeimies; S Karrer; H Bäcker
Journal:  Hautarzt       Date:  2005-05       Impact factor: 0.751

3.  A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment.

Authors:  C S Jury; V S Ramraka-Jones; V Gudi; R M Herd
Journal:  Br J Dermatol       Date:  2005-10       Impact factor: 9.302

4.  Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.

Authors:  Neil Korman; Ron Moy; Mark Ling; Robert Matheson; Stacy Smith; Scott McKane; James H Lee
Journal:  Arch Dermatol       Date:  2005-04

5.  Ras gene mutation and amplification in human nonmelanoma skin cancers.

Authors:  W E Pierceall; L H Goldberg; M A Tainsky; T Mukhopadhyay; H N Ananthaswamy
Journal:  Mol Carcinog       Date:  1991       Impact factor: 4.784

6.  Prevalence of solar damage and actinic keratosis in a Merseyside population.

Authors:  A A Memon; J A Tomenson; J Bothwell; P S Friedmann
Journal:  Br J Dermatol       Date:  2000-06       Impact factor: 9.302

7.  Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.

Authors:  Neil Swanson; William Abramovits; Brian Berman; James Kulp; Darrell S Rigel; Sharon Levy
Journal:  J Am Acad Dermatol       Date:  2010-02-04       Impact factor: 11.527

8.  Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers.

Authors:  A Zaravinos; P Kanellou; D A Spandidos
Journal:  Br J Dermatol       Date:  2009-08-29       Impact factor: 9.302

9.  Diagnostic concordance among dermatopathologists using a three-tiered keratinocytic intraepithelial neoplasia grading scheme.

Authors:  Frances I Ramos-Ceballos; Songthip T Ounpraseuth; Thomas D Horn
Journal:  J Cutan Pathol       Date:  2008-04       Impact factor: 1.587

Review 10.  Cryosurgery for common skin conditions.

Authors:  Mark D Andrews
Journal:  Am Fam Physician       Date:  2004-05-15       Impact factor: 3.292

View more
  2 in total

Review 1.  [The aged scalp : A dermato-oncological focus point].

Authors:  N Wroblewski; K Wylon; C Ulrich
Journal:  Hautarzt       Date:  2017-06       Impact factor: 0.751

Review 2.  [Actinic keratoses].

Authors:  T Hommel; R-M Szeimies
Journal:  Hautarzt       Date:  2016-11       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.